Haleon Adjusts FY26 Organic Revenue Growth To ~2.5%, High-Single-Digit Adjusted Operating Profit Growth At Constant Currency, Net Interest Of ~£255 Million, Incorporating China Centrum OTC Product Classification Changes And Accelerated Brazil Go-To-Market Model Rollout

Benzinga · 1d ago

2026 Outlook The FY 2026 guidance incorporates the impact from the raw material classification change impacting Centrum OTC-registered products in China and an expected impact of the acceleration of our new go-to-market model in Brazil. (See below). As a result, the Group now expects for FY 2026: Organic revenue growth to be around 2.5% High-single digit adjusted operating profit growth at constant currency Net interest c.£255m; Adjusted effective tax rate c.24.5%